Europe’s TTOs face a capacity gap as research patent activity doubles

By Priya Raman

The 809 European technology-transfer offices analysed in an EPO study were overwhelmingly small or mid-scale: 90.5% fell into those categories, while 9.5% counted as large-scale operations. The study also describes wide variation in office maturity and activity, without defining those measures.

That imbalance matters because large-scale offices had six times the staff of small or mid-scale peers. Their supported institutions had 23 times the research expenditure and nearly seven times the research workforce, while the offices received almost 16 times as many invention disclosures.

What is constraining technology transfer?

The study identifies six priorities intended to turn European research excellence into market success. EPO President António Campinos linked the agenda to stronger technology transfer, broader access to finance and a more integrated single market for innovation; the release does not enumerate all six priorities.

Campinos said: “Technology transfer is a competitiveness issue.” He added that Europe’s universities and public research organisations stand at the forefront of scientific discovery, but “breakthroughs must move from the lab to the market if they are to create jobs, growth and strategic autonomy.”

The operating evidence narrows the bottleneck. Once an invention enters a small or mid-scale office’s pipeline, the study says that office can progress it toward a patent, licence or venture at rates comparable to those of larger offices. No counts, success rates or interval estimates accompany that comparison.

The study attributes the difference to capacity. Large offices process substantially more activity per staff member because they have specialist expertise, established processes and stronger commercial networks. Most smaller offices cannot maintain every capability in-house.

The study’s proposed response keeps contact with researchers local while sharing specialist market knowledge, technology intelligence, training and investor access through regional and European support structures. For R&D managers, the model implies a division of labour: shared commercial, patent and investor services could reduce duplicated institution-level teams.

The cross-border dimension is growing. Research-based technologies now emerge from a wider set of countries, while the companies, investors and entrepreneurs best placed to develop them may sit elsewhere in Europe. The study argues that visibility, brokerage and cross-border links can match inventions to partners, although cross-border transfer still operates at a limited scale.

Where does the commercialisation gap appear?

Europe’s headline share of patents involving universities is close to the United States: about 9% of European patents. European universities also own a larger share of their inventions than they did 20 years ago, although the release gives no baseline percentage.

The outcome measure shows a gap. Of patents directly owned by European universities, 40.7% lapse within 10 years, compared with 26.3% for US university-owned patents. The release links this pattern to challenges in sustaining and commercialising promising technologies.

Lapse does not itself establish that an invention failed commercially, so the figures measure portfolio maintenance rather than realised returns. The release also points to intensifying competition, notably China’s renewed focus on university technology commercialisation in its 15th Five-Year Plan, as a reason for Europe to strengthen technology transfer support.

Which technologies show the largest public-research role?

European patent applications involving a university, public research organisation or research hospital more than doubled over 20 years, from about 3,200 in 2006 to almost 8,000 in 2025. Germany, France and the United Kingdom remain the leading countries, but their combined share fell from nearly 64% to about 55%.

The EPO presents that shift as geographic broadening rather than retreat by the three leaders. It cites particularly strong growth in the Netherlands and Spain, plus wider activity elsewhere, and identifies CNRS in France, Fraunhofer-Gesellschaft in Germany, CEA in France, Inserm in France and imec in Belgium among the leading public research institutions.

Research institutions were applicants on about 34% of European-origin biotechnology applications, 29% of quantum-technology applications and 26% of pharmaceutical applications in 2025. These shares measure filing participation, not the share of inventions licensed or commercialised; the release does not report field-level conversion outcomes.

What tools can R&D leaders use?

Alongside the study, the EPO launched a Data Desk dashboard for European public research. It lets users examine patenting activity by country, institution and technology, giving portfolio teams a way to compare institutional and national activity. The EPO also expanded its Deep Tech Finder with data on European public research organisations to support links among institutions, industry and investors.

The release does not identify a funder for the study, an observation period for most office data, the country sampling frame, office-size definitions or the patent-lapse method. It also gives no patent counts behind the 9% and lapse shares, and no numerical comparison of patent, licence or venture conversion rates.

The figures therefore support staffing and shared-service questions, not causal estimates or forecasts. The next test is whether EPO and regional support bodies can use shared expertise and new data tools to reduce lapses and connect Europe’s expanding public-research patent pipeline to sustained commercial activity.